The vast majority of children with sickle cell anemia (SCA) live in Africa, where evidence-based guidelines for primary stroke prevention are lacking. In Kano, Nigeria, we conducted a feasibility trial to determine the acceptability of hydroxyurea therapy for primary stroke prevention in children with abnormal transcranial Doppler (TCD) measurements. Children with SCA and abnormal non-imaging TCD measurements (200 cm/s) received moderate fixed-dose hydroxyurea therapy (20 mg/kg/day). A comparison group of children with TCD measurements <200 cm/s was followed prospectively. Approximately 88% (330 of 375) of families agreed to be screened, while 87% (29 of 33) of those with abnormal TCD measurements, enrolled in the trial. No participant elected to withdraw from the trial. The average mean corpuscular volume increased from 85.7 fl at baseline to 95.5 fl at 24 months (not all of the children who crossed over had a 24 month visit), demonstrating adherence to hydroxyurea. The comparison group consisted of initially 210 children, of which four developed abnormal TCD measurements, and were started on hydroxyurea. None of the monthly research visits were missed (n 5 total 603 visits). Two and 10 deaths occurred in the treatment and comparison groups, with mortality rates of 2.69 and 1.81 per 100 patient-years, respectively (P 5 .67). Our results provide strong evidence, for high family recruitment, retention, and adherence rates, to undertake the first randomized controlled trial with hydroxyurea therapy for primary stroke prevention in children with SCA living in Africa.
| I N T R O D U C T I O N
One of the most feared and devastating complications for children with sickle cell anemia (SCA) and their family is a stroke. In children with SCA in high-income countries, strokes are now mostly preventable. Abnormal transcranial Doppler (TCD) ultrasound screening coupled with regular blood transfusion therapy has resulted in a significant drop in the rate of strokes. 1, 2 In one tertiary care center in the United States, the stroke incidence rate dropped by approximately 10-fold (from 0.67 to 0.06 strokes per 100 patient-years) after initiation of routine TCD screening, with regular blood transfusion therapy for those with abnormal TCD measurements. 2 Unfortunately, in Africa, no systematic approach has been undertaken to prevent strokes in children with SCA. Nigeria is the country with the largest population of SCA in the world (approximately 150,000 births of children with SCA per year), 3 compared to the United
States (approximately 1,200 births of children with SCA per year). 4, 5 Major obstacles for primary stroke prevention in Nigeria include, but
are not limited to: the lack of access to TCD equipment and inadequate training of staff in detecting abnormal TCD measurements. Possibly the greatest challenge to primary stroke prevention in Africa is the inability to replicate the standard of care for primary stroke prevention present in high-income countries, specifically regular blood transfusion therapy for at least a year for those with abnormal TCD measurements. 6 Regular blood transfusion therapy for stroke prevention is not accepted as an option for most parents of children in Nigeria with SCA because of concerns about cost, safety of blood transfusion 7 and limited blood supply.
Given that regular blood transfusion therapy is not a viable option for primary stroke prevention for children living in Africa, we conducted a single-arm feasibility trial to determine the acceptability of moderate fixed-dose hydroxyurea ( 20 mg/kg/day) for primary stroke prevention in Nigerian children with SCA (NCT01801423; grant number 1R21NS080639). We tested the primary hypothesis that moderate fixeddose hydroxyurea therapy is a feasible intervention for children with SCA and TCD measurements 200 cm/s (non-imaging technique). We also established strategies for hydroxyurea toxicity monitoring in and creating stroke prevention teams in Nigeria beyond the setting of the clinical trial.
| M E T H O D S

| Study design
Ethical approval for the study was obtained from the Institutional ; (4) ability to swallow an empty (similar size to study therapy) pill capsule prior to treatment;
and (5) acceptance of hydroxyurea therapy with minimum follow-up period of 12 months on the study therapy. All eligible participants for the trial were offered regular blood transfusion therapy for primary stroke prevention.
The exclusion criteria included: (1) prior history of overt stroke, or concern for moderate to severe neurological deficit based on a positive validated "Ten questions" screening 9, 10 ; (2) other significant organ system dysfunction (any contraindication to hydroxyurea therapy); (3) history of seizures or diagnosis of epilepsy; (4) prior placement on regular blood transfusion or hydroxyurea therapy; (5) significant cytopenias (absolute neutrophil count < 1.5 3 10 9 /L, platelets < 150 3 10 9 /L). We excluded children less than five years of age due to the high mortality rate as well as malarial and bacterial infections seen in this age group in Nigeria.
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The comparison group consisted of individuals who signed the informed consent, had TCD measurements <200 cm/s in the MCA, and who agreed to be followed prospectively. The comparison group was followed with at least one standard care visit per year with planned at least monthly interim telephone calls to assess status. Participants in the comparison group could crossover to the therapy group, if during routine care, the TCD measurements were 200 cm/s in the MCA. The follow-up time for the comparison group is counted up until the date a participant crossed over to therapy, last day of follow-up or death, whichever came first.
| Certification in TCD ultrasound scans technique and neurology examination
Initially, two Nigerian radiologists recruited for the trial were trained and certified after demonstrating reproducibility in assessment of velocity in the MCA with an experienced ultrasonographer in the United Kingdom (who has been teaching nonimaging TCD procedure for two decades). The two on-site radiologists on the trial were certified only in assessing velocity in the MCA using a nonimaging TCD . [16] [17] [18] The MMAS-8 was previously validated for assessment of hydroxyurea adherence in children with SCA. 16 The MMAS-8 is scored as follow: high adherence (8 points), average adherence (6 to 7 points), and poor adherence (0 to 5 points).
| Sample size for feasibility trial
After funding of the trial, the AKTH IRB rejected a randomized controlled trial with a treatment and placebo arm of 40 abnormal TCD measurements; consequently, we elected to enroll 25 participants with abnormal TCD measurements to receive fixed-dose hydroxyurea therapy (treatment group) and 210 participants with TCD measurements < 200 cm/s to be followed prospectively (comparison group). The final sample size was based on budgetary restraints.
| Safety monitoring and evaluation for participants receiving moderate fixed-dose hydroxyurea therapy
Monitoring for unanticipated adverse effects was performed two weeks after starting hydroxyurea therapy for all participants; thereafter, monthly. A missed follow-up visit was defined as not being evaluated within two weeks of the scheduled monthly visit. An interval history of medical events and laboratory values were obtained monthly during the planned research visits for each participant. We developed a safety laboratory algorithm based on laboratory values in children with SCA followed at AKTH (https://medschool.vanderbilt.edu/cqs/spin-resources)
We also interviewed parents during monthly follow-up visits for participants receiving hydroxyurea therapy for assessment of indicators of stroke and adherence. Participants on hydroxyurea therapy were monitored with scheduled research visits monthly for cytopenias. We defined an adverse event as adverse reactions that are expected complications in children with SCA (including pain, acute chest syndrome, priapism, sepsis, splenic sequestration, hospitalization, and blood transfusion therapy). We defined severe adverse events as those leading to prolonged hospitalization beyond seven days, admission into the intensive care unit, near death, or death. We used the Common Toxicity Criteria for Adverse Events. 19 
| Evaluation for participants in the comparison group
On an ongoing basis (typically monthly), we reviewed the hospitaliza- 
| Early results indicate that moderate fixed-dose hydroxyurea therapy is safe
Serious adverse events and adverse events occurred with similar rates in both the treatment and comparison group, Table 2 In Africa, shortages of TCD machines and health care providers with the requisite skills to perform TCD testing (such as radiologists)
are major barriers to implementing routine TCD examinations. Obtaining accurate TCD measurements with certified ultrasonographers (physicians or non-physicians), who were not radiologists, was the ratelimiting step for our trial. To our knowledge, this is the first effort to establish a TCD training program in nonradiology physicians in Africa.
Local practices at our study sites in Nigeria, prevented non-physicians from learning TCD techniques. Our TCD training approach was successful with the inter-observer variability coefficient >0.8 among all
trainees when compared to the trainer. Ultimately, given the large number of children with SCA, when primary stroke prevention becomes a priority in Africa, radiologists will be needed to certify nonphysician ultrasonographers.
Previous studies demonstrated intra-and inter-observer variability were important sources of measurement error in TCD assessments. 25, 26 In addition to observer variability, poorly defined participant TCD variability (or intra-participant standard deviation) must be considered when interpreting TCD measurements. In children with SCA with two TCD measurements evaluated less than 6 months apart, the 95% confidence limit for change in steady state TCD measurement was 29 cm/s. 27 In the recently completed TCD with Transfusion
Changing to Hydroxyurea (TWITCH) trial, for children receiving blood transfusion therapy with at least 6 measurements, the average within participant variation was between 10.2 and 12.3 cm/s. 28 To minimize the contribution of participant TCD variability in assessment of intraobserver variability of the skilled radiologist (trainer), we elected for the trainer to repeat the TCD measurement in the same participant within a 3-hour time window. Our results demonstrated that even in the best of circumstances, there will be a 7-12% variability in the assessment of TCD when performed by a skilled radiologist in the same child on the same day. Together, these data validate our approach of utilizing entry criteria of two independent TCD values 200 cm/s or one value >220 cm/s, preferably performed by a second certified ultrasonographer.
Prior to starting the trial, we were uncertain of the appropriate hydroxyurea treatment dose (fixed-dose 10 mg/kg (low) versus fixeddose 20 mg/kg (moderate), or maximum tolerated dose). However, based on the hydroxycarbamide in very young children with SCA trial (BABY HUG) where participants were randomly allocated to moderate dose hydroxyurea therapy or placebo, 29 a moderate dose of hydroxyurea was not associated with rates of increased cytopenias.
The rate of significant cytopenia is no different than in children not on hydroxyurea. 29 Further, approximately 80% of the children in the trial dropped their TCD measurements to <200 cm/s, approximately three months after starting hydroxyurea therapy. 30, 31 In comparison, among participants in the Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) trial, after initiating regular blood transfusion therapy, 52% of the participants had normal TCD measurements after a mean of 4.3 months. 32 These data, coupled with those from the recently completed TWiTCH Trial demonstrating that hydroxyurea therapy was noninferior to blood transfusion for primary stroke prevention in children with abnormal TCD measurements, and no evidence of magnetic resonance cerebrovascular disease, after a year of regular blood transfusion therapy, 6 strongly suggest that moderate fixed-dose hydroxyurea therapy is a reasonable starting point for primary stroke prevention in Africa.
The vaccination rate was lower than anticipated. The inadequate PCV-13 and Hib vaccination coverage is most likely due to the considerable out-of-pocket expenses for those vaccines for families rather than any lack of counseling on the importance of receiving the vaccines. The median annual family income of $5490. The out-of-pocket cost for the one PCV-13 vaccination is $60 in Kano, Nigeria. Given the increased risk of infection and observed mortality rate in children with SCA, we believe expanding efforts to treat African children with SCA with hydroxyurea therapy should be coupled with efforts to ensure complete vaccination coverage, at least against S. pneumoniae and H.
influenzae.
As anticipated, the feasibility trial has inherent limitations. First, a median follow-up duration of just over two years does not fully address the concerns about retention for the phase III trial (planned therapy for a minimum of least three years), long-term toxicity of hydroxyurea, or whether hydroxyurea therapy has a durable impact on preventing strokes in children with abnormal TCD measurements. The third year was planned as a transition year between the initial R21 funding and receipt of funding for a phase III randomized controlled trial. As a result of funding from the National Institute of Neurological Disorders and Stroke (1R01NS094041), we will follow the participants in the current feasibility trial for a mean duration of six years. Additionally, with the new funding, the teams will conduct a RCT comparing moderate fixed-dose hydroxyurea therapy (20 mg/kg/day) to low fixed-dose hydroxyurea (10 mg/kg/day) therapy for primary stroke prevention in children with SCA. Second, the initial interval between obtaining the laboratory values and reviewing them in a timely fashion was less than optimal. To address the challenge, we recruited laboratory personnel allocated to the trial. We also instituted weekly reviews between the study site and coordinating center teams that included a local study monitor whose sole responsibility was to review all laboratory values and follow the safety algorithm. Finally, 10 of 12 reported deaths in the combined treatment and comparison groups occurred at home, with no further examinations performed to determine the cause of death-an intrinsic limitation in attributing cause of death in lowand middle-income countries. 33 In addition to these limitations, challenges relevant to adhering to regulatory guidelines, study medication, and evaluations were described in detail elsewhere. 
